Volume 15, Issue 59 (7-2025)
NCMBJ 2025, 15(59): 35-48 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hajimokhtari1 G, Jafary H, Kianmehr Z. Investigating the effect of alpha-amanitin on the proliferation of HepG2 cells cultured on the amniotic membrane containing HUVEC cells. NCMBJ 2025; 15 (59) :35-48
URL: http://ncmbjpiau.ir/article-1-1767-en.html
URL: http://ncmbjpiau.ir/article-1-1767-en.html
Department of Biology, SR. C., Islamic Azad University, Tehran, Iran , h-jafary@srbiau.ac.ir
Abstract: (14 Views)
Aim and Background: The use of chemical drugs to treat liver cancer has many side effects. Therefore, the use of a drug that can affect the survival of cancer cells with fewer side effects is of great importance. The aim of the present study was to investigate the inhibitory effect of alpha-amanitin on HepG2 cells.
Materials and Methods: In this study, HepG2 cells were cultured on amniotic membrane containing HUVEC and after treatment with alpha-amanitin, cell viability was assessed using MTT assay and apoptosis was assessed using flow cytometry. Malondialdehyde (MDA), superoxide dismutase (SOD) enzyme activity, total oxidant status (TOS) and total antioxidant capacity (TAC) were quantified using calorimetry. Tumor necrosis factor alpha (TNF-α) levels were assessed using immunocytochemistry (ICC).
Results: The results of the MTT test showed that the treatment of HepG2-Amnion and HepG2-Amnion-HUVEC cells with concentrations of 250 and 500 pg/ml of alpha-amanitin significantly reduced the viability of HepG2 cells. Also, the results of flow cytometry showed that the incidence of apoptosis in HepG2-Amnion-HUVEC and HepG2-Amnion cells treated with alpha-amanitin significantly increased. The results of the biochemical test showed an increase in the levels of MDA, TOS and a decrease in the levels of SOD and TAC in both groups co-cultured with amnion and Amnion-HUVEC and treated with alpha-amanitin. The results of the ICC showed that the expression of TNF-α protein in both groups treated with alpha-amanitin significantly increased.
Conclusion: Using amniotic membrane to culture HepG2 cells can result in a significant anticancer effect of alpha-amanitin on this type of cell.
Materials and Methods: In this study, HepG2 cells were cultured on amniotic membrane containing HUVEC and after treatment with alpha-amanitin, cell viability was assessed using MTT assay and apoptosis was assessed using flow cytometry. Malondialdehyde (MDA), superoxide dismutase (SOD) enzyme activity, total oxidant status (TOS) and total antioxidant capacity (TAC) were quantified using calorimetry. Tumor necrosis factor alpha (TNF-α) levels were assessed using immunocytochemistry (ICC).
Results: The results of the MTT test showed that the treatment of HepG2-Amnion and HepG2-Amnion-HUVEC cells with concentrations of 250 and 500 pg/ml of alpha-amanitin significantly reduced the viability of HepG2 cells. Also, the results of flow cytometry showed that the incidence of apoptosis in HepG2-Amnion-HUVEC and HepG2-Amnion cells treated with alpha-amanitin significantly increased. The results of the biochemical test showed an increase in the levels of MDA, TOS and a decrease in the levels of SOD and TAC in both groups co-cultured with amnion and Amnion-HUVEC and treated with alpha-amanitin. The results of the ICC showed that the expression of TNF-α protein in both groups treated with alpha-amanitin significantly increased.
Conclusion: Using amniotic membrane to culture HepG2 cells can result in a significant anticancer effect of alpha-amanitin on this type of cell.
Type of Study: Research Article |
Subject:
Biochemistry
Received: 2025/09/8 | Accepted: 2025/07/1 | Published: 2025/07/1
Received: 2025/09/8 | Accepted: 2025/07/1 | Published: 2025/07/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
